tiprankstipranks
Advertisement
Advertisement
Marker Therapeutics: Upcoming MT-601 and MT-401 Catalysts Support Buy Rating and $8 Target on Favorable Risk-Reward
PremiumRatingsMarker Therapeutics: Upcoming MT-601 and MT-401 Catalysts Support Buy Rating and $8 Target on Favorable Risk-Reward
2M ago
Marker Therapeutics reports FY25 EPS (79c), two estimates (94c)
Premium
The Fly
Marker Therapeutics reports FY25 EPS (79c), two estimates (94c)
2M ago
Marker Therapeutics (MRKR) Q4 Earnings Cheat Sheet
Premium
Pre-Earnings
Marker Therapeutics (MRKR) Q4 Earnings Cheat Sheet
2M ago
Marker Therapeutics initiated with a Buy at H.C. Wainwright
PremiumThe FlyMarker Therapeutics initiated with a Buy at H.C. Wainwright
5M ago
Marker Therapeutics Reports Q3 2025 Financial Results
Premium
Company Announcements
Marker Therapeutics Reports Q3 2025 Financial Results
6M ago
Marker Therapeutics Announces Positive APOLLO Study Results and Strategic Advances
Premium
Company Announcements
Marker Therapeutics Announces Positive APOLLO Study Results and Strategic Advances
6M ago
Marker Therapeutics’ MT-601 Study: A Promising Step in Lymphoma Treatment
PremiumCompany AnnouncementsMarker Therapeutics’ MT-601 Study: A Promising Step in Lymphoma Treatment
7M ago
Marker Therapeutics Advances Off-the-Shelf T Cell Therapy with First Patient Treatment
Premium
Company Announcements
Marker Therapeutics Advances Off-the-Shelf T Cell Therapy with First Patient Treatment
8M ago
Marker Therapeutics announces first patient treated in off-the-shelf program
Premium
The Fly
Marker Therapeutics announces first patient treated in off-the-shelf program
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100